Baxter Healthcare was among the investors in the $65m first close of a private placement the biosimilar drug developer has pushed to $100m.

Alphabet subsidiary GV was part of a consortium in a round that will fund the progress of the precision medicine developer's lead drug candidate into the clinic.

The biopharmaceutical company has provided $40m in seed capital for the newly launched immuno-oncology drug developer.

Osaka spinout Cuorips has added $14.7m to its coffers from investors including CellSource and Fujifilm, just three months after collecting $19.3m.

RA Capital Management and Rock Springs Capital have co-led a series B round for the gene editing technology developer spun out of Stanford six months ago.

Feature: artificial intelligence driving disease prevention, digital health enables personalised medicine, investment takes off

Reza Halse will be a partner at RA Capital, which held a first and final closing of its second venture fund in October. 

China Merchants Group led a series C round for the antibody drug developer that was also backed by fellow corporates Tigermed and Dawn.

Boehringer Ingelheim Venture Fund returned to reinvest in the regenerative therapy developer after backing its series A round two years ago.

The Future Value Fund I will invest in pre-seed companies, including spinouts from Rev1's long-time partner Ohio State University.